Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,783 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Shah MA, et al. Among authors: ford j. PLoS One. 2021 Dec 23;16(12):e0261994. doi: 10.1371/journal.pone.0261994. eCollection 2021. PLoS One. 2021. PMID: 34941969 Free PMC article.
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Shah MA, et al. Among authors: ford j. PLoS One. 2013;8(3):e54014. doi: 10.1371/journal.pone.0054014. Epub 2013 Mar 14. PLoS One. 2013. PMID: 23516391 Free PMC article. Clinical Trial.
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Shah MA, et al. Among authors: ford j. PLoS One. 2022 Oct 10;17(10):e0276211. doi: 10.1371/journal.pone.0276211. eCollection 2022. PLoS One. 2022. PMID: 36215283 Free PMC article.
Integrated framework for quantitative T2-weighted MRI analysis following prostate cancer radiotherapy.
Zacharaki EI, Breto AL, Algohary A, Wallaengen V, Gaston SM, Punnen S, Castillo P, Pattany PM, Kryvenko ON, Spieler B, Ford JC, Abramowitz MC, Dal Pra A, Pollack A, Stoyanova R. Zacharaki EI, et al. Among authors: ford jc. Phys Imaging Radiat Oncol. 2024 Oct 24;32:100660. doi: 10.1016/j.phro.2024.100660. eCollection 2024 Oct. Phys Imaging Radiat Oncol. 2024. PMID: 39563782 Free PMC article.
Indigenous knowledge and leadership for climate change adaptation in nutrition.
Zavaleta-Cortijo C, Silvera-Ccallo R, Lancha-Rucoba G, Chanchari J, Inuma N, Pizango M, Morales-Ancajima V, Miranda-Cuadros M, Aparco JP, Valdivia-Gago A, Nunta-Guimaraes R, Antazú T, Velez-Quevedo J, Fernandez-Neyra C, Carcamo C, Greenwood D, Cade J, Ford JD, Harper S, Miranda JJ. Zavaleta-Cortijo C, et al. Among authors: ford jd. PLOS Glob Public Health. 2024 Nov 14;4(11):e0003917. doi: 10.1371/journal.pgph.0003917. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39541399 Free PMC article. No abstract available.
3,783 results